Danaher Corp.DHR

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NYSE · United States · danaher.com

Danaher Corporation is a global life sciences and diagnostics company headquartered in Washington, D.C., operating through three segments: Biotechnology (bioprocessing and discovery tools), Life Sciences (instruments and consumables for genomics and cellular research), and Diagnostics (clinical instruments, reagents, and services for disease diagnosis). The company serves pharmaceutical manufacturers, scientific research laboratories, and hospitals worldwide with specialized equipment, software, and consumables. Danaher applies its proprietary Danaher Business System to drive continuous improvement and operational excellence across its portfolio of scientific brands.

Key ratios

Operating cash flow growth

7.6%TTM

2025 -4.1%2024 -6.6%2023 -15.9%

EPS growth

19.2%TTM

2025 -4.9%2024 -6.4%2023 -33.3%

FCF / Sales

21.4%TTM

2025 21.4%2024 22.2%2023 24.2%

Net margin

16.0%TTM

2025 14.7%2024 16.3%2023 19.9%

ROA

4.0%TTM

2025 4.2%2024 4.0%2023 3.9%

ROE

7.6%TTM

2025 7.1%2024 7.6%2023 8.2%

Revenue growth

4.6%TTM

2025 2.9%2024 -0.1%2023 -10.3%

Recent news

Danaher Completes Acquisition of Masimo Corporation 2026-06-10 · PR Newswire Danaher Announces Quarterly Dividend 2026-05-05 · PR Newswire

Track DHR in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer